H.C. Wainwright reaffirms USD 130 target for Halozyme Therapeutics stock

Published on 10/20/2026 at 18:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 481.00 million, up 47.70 percent. Halozyme Therapeutics stock costs EUR 110.23 on October 20, 2026.

Analyst target and reporting date

H.C. Wainwright reaffirmed a Buy rating and a USD 130.00 target on October 15, 2026.
Second-quarter revenue reached USD 481.00 million, up 47.70 percent year over year.
Halozyme Therapeutics stock costs EUR 110.23 at Lang & Schwarz on October 20, 2026 at 6:32 p.m. CEST.
The next earnings report is expected on November 2, 2026.

HALO, US40637H1095, Illustration mit AI erstellt.

Halozyme Therapeutics (ISIN US40637H1095) has a USD 130.00 price target from H.C. Wainwright after the research firm reaffirmed its Buy rating on October 15, 2026. The target stands 5.14 percent above the USD 123.64 Nasdaq price at the latest quoted US session point. At Lang & Schwarz, the stock was trading at EUR 110.23 on October 20, 2026 at 6:32 p.m. CEST.

Revenue growth remains central

Halozyme reported USD 481.00 million in revenue for the second quarter of 2026, up 47.70 percent from USD 325.72 million in the second quarter of 2025, according to Markets Insider. The same report puts quarterly net profit at USD 229.91 million, versus USD 165.16 million a year earlier.

Stock stays near its yearly high

Halozyme's latest USD quote was USD 123.64 at 12:37 p.m. ET on October 20, 2026. Its 52-week range was USD 61.23 to USD 125.10, placing the latest quote 1.17 percent below the high. The stock had a market capitalization of USD 14.0 billion and a price-to-earnings ratio of 36.91 on the same date.

Guidance and the next date

For fiscal year 2026, Halozyme set non-GAAP earnings-per-share guidance at USD 8.65 to USD 9.00, while MarketBeat reported that analysts expected USD 8.31 for the year. The guidance range and quarterly results were reported by MarketBeat. A market calendar lists November 2, 2026 as the expected date for the next report, with third-quarter 2026 revenue estimated at USD 490.85 million, according to MetaCap.

What the target implies

H.C. Wainwright's USD 130.00 target sits above the latest Nasdaq quote, while the broader consensus target cited by MarketBeat was USD 96.50. That gap shows how differently analysts value Halozyme's royalty growth and its drug-delivery partnerships.

Current trading level

Halozyme Therapeutics was trading at EUR 110.23 at Lang & Schwarz on October 20, 2026 at 6:32 p.m. CEST. The company develops subcutaneous drug-delivery technologies through its ENHANZE platform and licenses them to pharmaceutical partners. The further course of trading is shown by the continuously updated real-time quote of Halozyme Therapeutics stock.